Triple-bead MAS: Phase III data

Top-line data from double-blind, U.S. Phase III SHP465-305 trial in about 264 ADHD patients ages 6-17 showed that once-daily oral SHP465 taken in the morning met the primary

Read the full 282 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE